HRP20231613T1 - Pripravci koji sadrže sredstvo za unošenje i njihova priprava - Google Patents

Pripravci koji sadrže sredstvo za unošenje i njihova priprava Download PDF

Info

Publication number
HRP20231613T1
HRP20231613T1 HRP20231613TT HRP20231613T HRP20231613T1 HR P20231613 T1 HRP20231613 T1 HR P20231613T1 HR P20231613T T HRP20231613T T HR P20231613TT HR P20231613 T HRP20231613 T HR P20231613T HR P20231613 T1 HRP20231613 T1 HR P20231613T1
Authority
HR
Croatia
Prior art keywords
preparation according
pharmaceutical preparation
glp
pharmaceutical
lubricant
Prior art date
Application number
HRP20231613TT
Other languages
English (en)
Inventor
Thomas Vilhelmsen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49221869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20231613(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HRP20231613T1 publication Critical patent/HRP20231613T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (17)

1. Pripravak koji sadrži granulu koja sadrži sol N-(8-(2-hidroksibenzoil)amino)kaprilne kiseline i mazivo, naznačen time što se navedenu granulu proizvodi suhim granuliranjem, te dobiva miješanjem navedene soli N-(8-(2-hidroksibenzoil)amino)kaprilne kiseline s navedenim mazivom u trajanju od više od 5 minuta prije suhog granuliranja, što je količina navedenog maziva najmanje 2% (tež./tež.) od navedene granule, što pripravak sadrži jedan ili više intragranularnih dijelova i ekstragranularni dio, što su jedan ili više intragranularnih dijelova granulirani, te što se ekstragranularni dio doda nakon granuliranja.
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što navedeno miješanje traje 10, 20 ili 30 minuta.
3. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeno miješanje traje najmanje 30 minuta ili najmanje 40 minuta, primjerice najmanje 50 minuta.
4. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je količina navedenog maziva najviše 10 % (tež./tež.), primjerice najviše 8, 7 ili 6 % (tež./tež.), od navedene granule.
5. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je mazivo magnezijev stearat.
6. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeno miješanje traje najviše 12 sata, primjerice najviše 10, 8, 6, 4 ili 2 sata.
7. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedene granule se proizvodi komprimiranjem valjcima.
8. Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedena sol N-(8-(2-hidroksibenzoil)amino)kaprilne kiseline natrijev N-(8-(2-hidroksibenzoil)amino)kaprilat (SNAC).
9. Farmaceutski pripravak comprising a pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što pripravak sadrži jedan ili više intragranularnih dijelova i ekstragranularni dio, što su jedan ili više intragranularnih dijelova granulirani, te što se ekstragranularni dio doda nakon granuliranja.
10. Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time što farmaceutski pripravak dodatno sadrži farmaceutski aktivni sastojak, poput peptida GLP-1.
11. Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time što navedeni peptid GLP-1 sadrži skupinu kojem se veže na albumin.
12. Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time što navedeni peptid GLP-1 sadrži supstituent, kovalentno vezan na peptid, poput masne kiseline ili masne dikiseline.
13. Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time što je navedeni peptid GLP-1 semaglutid, poznat i kao Nε26-[2-(2-{2-[2-(2-{2-[(S)-4-karboksi-4-(17-karboksiheptadekanoilamino)butirilamino]etoksi}etoksi)acetilamino]etoksi}etoksi)acetil][Aib8,Arg34]GLP-1(7-37).
14. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva 9-13, naznačen time što navedeni farmaceutski pripravak dodatno sadrži jedno ili više farmaceutski prihvatljivih pomoćnih sredstava, poput jednog ili više sastojaka, koje se bira iz skupine koju čine punilo, poput mikrokristalne celuloze, te veziva, poput povidona.
15. Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva 9-14, naznačen time što je navedeni farmaceutski pripravak u obliku čvrstog oblika doziranja, poput tablete, kapsule ili vrećice.
16. Farmaceutski pripravak u skladu s patentnim zahtjevom 15, naznačen time što navedeni farmaceutski pripravak treba primijeniti oralno/oralnom primjenom.
17. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 9-16, naznačen time što je namijenjen upotrebi u medicini, primjerice u liječenju dijabetesa ili pretilosti.
HRP20231613TT 2012-03-22 2013-03-15 Pripravci koji sadrže sredstvo za unošenje i njihova priprava HRP20231613T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12160742 2012-03-22
US201361748844P 2013-01-04 2013-01-04
EP13153422 2013-01-31
EP18212576.5A EP3542790B1 (en) 2012-03-22 2013-03-15 Compositions comprising a delivery agent and preparation thereof

Publications (1)

Publication Number Publication Date
HRP20231613T1 true HRP20231613T1 (hr) 2024-03-15

Family

ID=49221869

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20231613TT HRP20231613T1 (hr) 2012-03-22 2013-03-15 Pripravci koji sadrže sredstvo za unošenje i njihova priprava

Country Status (11)

Country Link
US (1) US10335369B2 (hr)
EP (3) EP3542790B1 (hr)
JP (1) JP6356660B2 (hr)
CN (3) CN111494323B (hr)
ES (1) ES2965469T3 (hr)
HR (1) HRP20231613T1 (hr)
HU (1) HUE064694T2 (hr)
PL (2) PL2827845T3 (hr)
RS (2) RS64942B1 (hr)
SI (1) SI2827845T1 (hr)
WO (1) WO2013139695A1 (hr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
WO2012140117A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
ES2952874T3 (es) 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
RS64942B1 (sr) 2012-03-22 2024-01-31 Novo Nordisk As Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
KR20180115814A (ko) 2013-05-02 2018-10-23 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
CN104173313B (zh) * 2014-08-25 2017-05-17 杭州朱养心药业有限公司 利伐沙班片剂药物组合物
CA2973099C (en) 2015-01-12 2021-09-14 Enteris Biopharma, Inc. Solid oral dosage forms
WO2018121702A1 (zh) * 2016-12-30 2018-07-05 江苏恒瑞医药股份有限公司 一种glp-1类似物的药物组合物及其制备方法
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
MA53076B1 (fr) * 2018-02-02 2023-11-30 Novo Nordisk As Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN113329810A (zh) * 2019-01-24 2021-08-31 诺和诺德股份有限公司 辊压机和使用辊压机的干法制粒方法
WO2021023855A1 (en) * 2019-08-07 2021-02-11 Novo Nordisk A/S Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN114340655A (zh) 2019-09-02 2022-04-12 诺和诺德股份有限公司 生产包含glp-1肽的片剂的方法
WO2021043971A1 (en) 2019-09-06 2021-03-11 Novo Nordisk A/S Method and equipment for fractionation of granules for use in pharmaceutical compositions
JP2023502004A (ja) 2019-11-07 2023-01-20 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬、ｓｇｌｔ２阻害剤、およびｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む固形組成物
JP2023524695A (ja) * 2020-04-29 2023-06-13 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
BR112023000270A2 (pt) 2020-07-22 2023-01-31 Novo Nordisk As Composto, composição farmacêutica, e, peptídeo
CN116157414A (zh) * 2020-07-22 2023-05-23 诺和诺德股份有限公司 Glp-1和gip受体共激动剂
CN113117050B (zh) * 2021-05-06 2022-04-26 合肥天汇孵化科技有限公司 多肽组合物及其用途
IL308280A (en) 2021-05-07 2024-01-01 Lilly Co Eli Tablet worn out
WO2023285580A1 (en) 2021-07-15 2023-01-19 Novo Nordisk A/S Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CA3239474A1 (en) * 2021-12-01 2023-06-08 Hua He Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH24180A (en) 1986-03-12 1990-03-22 Glaxo Group Ltd Macrolide compounds,pharmaceutical composition containing said compound and method of use thereof
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
DE69737479D1 (de) 1996-08-30 2007-04-26 Novo Nordisk As Glp-1 derivate
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
JP2002504518A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
WO1999043707A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
DE60023841T2 (de) 1999-02-05 2006-05-24 Emisphere Technologies, Inc. Verfahren zur herstellung alkylierter salicylamide
CA2363123C (en) 1999-02-22 2011-09-06 Kenneth Iain Cumming Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
AU3240900A (en) 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
JP5196701B2 (ja) 2001-11-29 2013-05-15 エミスフィアー テクノロジーズ インコーポレイテッド クロモリンナトリウムの経口投与用製剤
KR100676025B1 (ko) 2002-02-01 2007-01-29 화이자 프로덕츠 인코포레이티드 아지쓰로마이신의 건조 과립화 제제
WO2003072195A2 (en) 2002-02-20 2003-09-04 Eli Lilly And Company Method for administering glp-1 molecules
JP2004131398A (ja) * 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
EP1624882A2 (en) 2003-05-14 2006-02-15 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
JP5032844B2 (ja) 2003-07-11 2012-09-26 ノバルティス アーゲー 微粉末形態の送達物質を含む経口投与用医薬組成物
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
KR20060109940A (ko) 2003-12-18 2006-10-23 노보 노르디스크 에이/에스 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
ATE461217T1 (de) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1-verbindungen
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
MXPA06012841A (es) * 2004-05-06 2007-02-15 Emisphere Tech Inc Forma de dosificacion solida de heparina humeda.
JP5254610B2 (ja) 2004-05-14 2013-08-07 エミスフェアー・テクノロジーズ・インク 活性薬剤を送達するための化合物および組成物
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
EP2289560B1 (en) 2004-07-08 2015-04-22 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US20060078622A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
JP5175553B2 (ja) * 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
BRPI0608516A2 (pt) 2005-03-18 2010-11-16 Novo Nordisk As análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
US20080260818A1 (en) 2005-03-28 2008-10-23 Dexcel Pharma Technologies Ltd. Controlled Absorption of Statins in the Intestine
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
AU2006318815B2 (en) 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition
WO2007117706A2 (en) 2006-04-07 2007-10-18 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
JP2009539862A (ja) 2006-06-09 2009-11-19 メリオン リサーチ Ｉｉｉ リミテッド 強化剤を含む固体経口投与剤形
CA2656019C (en) * 2006-06-28 2016-09-13 Emisphere Technologies, Inc. Gallium nitrate formulations
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
EP2057189B1 (en) 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
CA2662080C (en) 2006-09-07 2012-07-17 F. Hoffmann-La Roche Ag A process for the manufacture of snac (salcaprozate sodium)
WO2008039351A2 (en) 2006-09-22 2008-04-03 Novartis Ag Method of manufacturing tablets containing pharmacologically active agents
WO2008070547A1 (en) * 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
MX2009009243A (es) 2007-03-02 2009-09-08 Novartis Ag Administracion oral de una calcitonina.
WO2009032749A2 (en) 2007-08-29 2009-03-12 The Regents Of The University Of Californina Salicylanilide modified peptides for use as oral therapeutics
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
JP2010538049A (ja) 2007-09-05 2010-12-09 ノボ・ノルデイスク・エー／エス 切断型ｇｌｐ−１誘導体及びその治療的使用
NZ585135A (en) 2007-10-16 2012-08-31 Biocon Ltd An orally administerable solid pharmaceutical composition comprising in-105 and a process thereof
ES2443817T3 (es) 2007-11-02 2014-02-20 Emisphere Technologies, Inc. Método para tratar la deficiencia de vitamina B12
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
EP2331072B8 (en) * 2008-08-18 2020-08-26 Entera Bio Ltd. Methods and compositions for oral administration of proteins
KR20160143897A (ko) * 2009-02-13 2016-12-14 베링거 인겔하임 인터내셔날 게엠베하 Ｄｐｐ－４ 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제
CA2784120A1 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2011116139A2 (en) 2010-03-16 2011-09-22 Chiasma Inc. Improved pharmaceutical compositions and methods of delivery
EA033415B1 (ru) 2010-05-05 2019-10-31 Boehringer Ingelheim Int Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
RS64942B1 (sr) 2012-03-22 2024-01-31 Novo Nordisk As Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema
ES2952874T3 (es) 2012-03-22 2023-11-06 Novo Nordisk As Composiciones de péptidos GLP-1 y preparación de estas
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
KR20180115814A (ko) 2013-05-02 2018-10-23 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여

Also Published As

Publication number Publication date
RS58636B1 (sr) 2019-05-31
JP6356660B2 (ja) 2018-07-11
EP4331667A2 (en) 2024-03-06
CN111494323A (zh) 2020-08-07
CN104203221A (zh) 2014-12-10
PL2827845T3 (pl) 2019-06-28
ES2965469T3 (es) 2024-04-15
EP4331667A3 (en) 2024-05-08
US20150031606A1 (en) 2015-01-29
US10335369B2 (en) 2019-07-02
CN111494323B (zh) 2023-03-28
EP2827845A1 (en) 2015-01-28
EP2827845B1 (en) 2018-12-26
EP3542790A1 (en) 2019-09-25
CN111494324A (zh) 2020-08-07
CN111494324B (zh) 2023-05-16
RS64942B1 (sr) 2024-01-31
EP3542790C0 (en) 2023-09-13
PL3542790T3 (pl) 2024-02-26
WO2013139695A1 (en) 2013-09-26
HUE064694T2 (hu) 2024-04-28
EP3542790B1 (en) 2023-09-13
SI2827845T1 (sl) 2019-04-30
JP2015515459A (ja) 2015-05-28

Similar Documents

Publication Publication Date Title
HRP20231613T1 (hr) Pripravci koji sadrže sredstvo za unošenje i njihova priprava
HRP20231205T1 (hr) Čvrsti pripravci koji sadrže agonist glp-1, sol n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline i mazivo
RU2641198C3 (ru) Композиции glp-1 пептидов и их получение
JP2015515459A5 (hr)
JP2015512374A5 (hr)
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
HRP20180425T1 (hr) Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
TWI829687B (zh) 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
ES2436152T3 (es) Uso de calcitonina en osteoartritis
HRP20230075T1 (hr) Čvrsti pripravci namijenjeni oralnoj primjeni
JP2015038135A5 (hr)
JP2011026348A5 (hr)
SI3079671T1 (en) Oral disintegration solid dosage form containing an esterol component
RU2012100709A (ru) Новые фармацевтические композиции, содержащие прегабалин
TW202114730A (zh) 包括有glp-1促進劑、sglt2抑制劑及n-(8-(2-羥基苯甲醯基)胺基)辛酸鹽之固體組成物
HRP20190550T1 (hr) Formule i metode proizvodnje formulacija za upotrebu u pražnjenju debelog crijeva
CN102573463A (zh) N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法
RU2014115287A (ru) Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения
RU2019133551A (ru) Прероральное поступление физиологически активных веществ
AR105184A1 (es) Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos
Jeevanandham et al. Formulation and evaluation of naproxen sodium orodispersible tablets –A sublimation technique
JP2014527506A5 (hr)
JP2005535689A5 (hr)
JP2015120758A5 (hr)
JPWO2021023811A5 (hr)